| Edelman, Martin J |
| Completed | 2 | 90 | Europe, US | avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063 | Verastem, Inc. | Non Small Cell Lung Cancer, KRAS Activating Mutation | 08/23 | 12/23 | | |
|
| Recruiting | 1 | 250 | Europe, Canada, US, RoW | ADP adoptive cell therapy | Adaptimmune | Neoplasms | 04/32 | 04/32 | | |
NCT06222242: mychoiceTM Implementation With Medical Oncology Patients |
|
|
| Recruiting | N/A | 200 | US | mychoiceTM | Fox Chase Cancer Center, Genentech, Inc. | Cancer | 06/25 | 06/25 | | |
| Rapoport, Aaron P |
| Recruiting | 1 | 250 | Europe, Canada, US, RoW | ADP adoptive cell therapy | Adaptimmune | Neoplasms | 04/32 | 04/32 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
| Rolfo, Christian |
NCT05119933: A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation |
|
|
| Recruiting | 1/2 | 55 | US | YL-15293 | Shanghai YingLi Pharmaceutical Co. Ltd., Yingli Pharma US, Inc | Advanced Solid Tumor | 06/23 | 12/23 | | |
| Active, not recruiting | 1/2 | 856 | Europe, Canada, Japan, US, RoW | LOXO-292, Selpercatinib, LY3527723 | Loxo Oncology, Inc., Eli Lilly and Company | Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor | 02/25 | 02/26 | | |
|
|
|
|
|
|
|
| Hardy, Nancy M |
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation |
|
|
| Terminated | 3 | 130 | US | AB-205, E-CEL cells, Placebo | Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM) | Hodgkin Lymphoma, Non Hodgkin Lymphoma | 12/23 | 01/25 | | |
| Recruiting | 2 | 110 | US | zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine | Miltenyi Biomedicine GmbH | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma | 12/24 | 12/26 | | |
| Recruiting | 1 | 75 | US | CNTY-101, IL-2, Lymphodepleting Chemotherapy | Century Therapeutics, Inc. | R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma | 08/25 | 08/27 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
NCT06116110: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU |
|
|
| Not yet recruiting | N/A | 150 | US | Long-term Follow-Up | Miltenyi Biomedicine GmbH | Non Hodgkin Lymphoma | 12/39 | 12/39 | | |
NCT05768269: A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product |
|
|
| Recruiting | N/A | 375 | US | No Intervention | Century Therapeutics, Inc. | Hematological Malignancy, Solid Tumor Malignancy | 03/40 | 03/40 | | |
| Tkaczuk, Katherine |
| Completed | 1/2 | 186 | Europe, US, RoW | ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA® | Seagen Inc., Merck Sharp & Dohme LLC | Triple Negative Breast Neoplasms | 09/24 | 09/24 | | |
| Young, Cheryl |
NCT05975060: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. |
|
|
| Completed | 2/3 | 660 | US | XBB.1.5 Vaccine (Booster), Omicron sub variant XBB.1.5 vaccine( booster) SARS-CoV-2 rS /Matrix-M Adjuvant, XBB.1.5 Vaccine (single dose), Omicron sub variant XBB.1.5 vaccine(single dose) SARS-CoV-2 rS /Matrix-M Adjuvant | Novavax | COVID-19 | 11/23 | 05/24 | | |
| Harper, Jill |
| Terminated | 1 | 25 | US | FT-7051 | Novo Nordisk A/S | Metastatic Castration-resistant Prostate Cancer | 11/22 | 11/22 | | |
NCT06257693: Enzalutamide Implants (Enolen) in Patients With Prostate Cancer |
|
|
| Recruiting | 1 | 20 | US | enzalutamide, Radical prostatectomy | Alessa Therapeutics Inc., National Cancer Institute (NCI) | Prostate Adenocarcinoma | 06/25 | 08/25 | | |
| Scilla, Katherine |
NCT04699838: Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | US | Cisplatin, Carboplatin, Etoposide, Durvalumab, Ceralasertib | Muhammad Furqan, AstraZeneca | Extensive Stage Small Cell Lung Cancer | 09/25 | 09/25 | | |
NCT04499053: Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 18 | US | Durvalumab, Tremelimumab | Georgetown University, AstraZeneca | Carcinoma, Non-Small Cell Lung | 02/27 | 12/27 | | |
NCT03918252: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma |
|
|
| Active, not recruiting | 2 | 30 | US | Nivolumab Injection, Optivo, Ipilimumab Injection, Yervoy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Mesothelioma | 06/25 | 06/26 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT05374538: VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer |
|
|
| Terminated | 1a/1b | 4 | US | VIC-1911, sotorasib, LUMAKRAS | Vitrac Therapeutics, LLC, Westat | Non-small Cell Lung Cancer | 08/23 | 08/23 | | |
LIQUIK, NCT04703153: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | N/A | 151 | US | | Lucence Health Inc. | Non Small Cell Lung Cancer | 12/22 | 12/24 | | |
| Jennifer |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
| Alimurong, Joann |
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC |
|
|
| Active, not recruiting | 2 | 95 | Europe, US | Pembrolizumab (KEYTRUDA®) and PDS0101 | PDS Biotechnology Corp., Merck Sharp & Dohme LLC | Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck | 06/25 | 06/25 | | |
|
